Inivata

High-Level Overview

Inivata is a clinical-stage liquid biopsy company that develops non-invasive cancer diagnostics using circulating tumor DNA (ctDNA) analysis from a simple blood draw.[1][2][3] Its core InVision® platform provides genomic insights to guide personalized cancer treatment, monitor response, and detect relapse or residual disease, primarily serving oncologists, clinicians treating advanced non-small cell lung cancer (NSCLC) patients, and biopharma partners in drug development.[1][2] Key products include InVisionFirst®-Lung, commercially available internationally and in the US via NeoGenomics, and the RaDaR® assay, a highly sensitive personalized test for minimal residual disease (MRD) and recurrence, which earned FDA Breakthrough Device Designation.[1][2] Inivata solves the problem of invasive tissue biopsies by enabling faster, more accessible molecular profiling for therapy selection and resistance monitoring.[3] The company demonstrated strong growth through clinical validations, biopharma partnerships, and its acquisition by NeoGenomics in 2021, which accelerated commercialization and R&D.[1][2][7]

Origin Story

Founded in 2014, Inivata emerged from pioneering research in the Cancer Research UK-funded laboratory of Nitzan Rosenfeld at the Cancer Research UK Cambridge Institute, University of Cambridge.[1][2][6] This academic foundation focused on harnessing ctDNA for cancer detection, leading to the development of Inivata's proprietary InVision® platform.[1][2] Early traction came from launching InVisionFirst®-Lung for NSCLC and expanding into personalized assays like RaDaR®, with proof-of-principle data showing 100% specificity and sensitivity in head/neck and breast cancer cohorts.[1] Backed by investors like Cambridge Innovation Capital and Rosetta Capital, Inivata built CLIA-certified labs in Research Triangle Park, NC, and R&D facilities in Cambridge, UK, before its acquisition by NeoGenomics in May/June 2021, marking a pivotal commercialization milestone.[1][2][7]

Core Differentiators

Inivata stands out in liquid biopsy through:

• Superior Sensitivity and Specificity: RaDaR® assay achieves 100% specificity/sensitivity for MRD detection in key cancers, validated clinically and granted FDA Breakthrough Device Designation.[1][2]
• Non-Invasive, Actionable Insights: InVision® platform delivers rapid genomic profiling from blood, enabling therapy guidance, response monitoring, and resistance detection without tissue biopsies.[1][3]
• Proven Clinical and Commercial Products: InVisionFirst®-Lung offers competitive turnaround for NSCLC, available globally; extensive biopharma partnerships support early/late-stage trials.[1][2]
• Robust Infrastructure: CLIA/CAP-accredited US lab and UK R&D, enhanced post-acquisition by NeoGenomics for scaled commercialization.[1]

Role in the Broader Tech Landscape

Inivata rides the liquid biopsy megatrend in precision oncology, where ctDNA analysis shifts cancer care from invasive procedures to scalable blood tests amid rising demand for personalized medicine.[1][3] Timing aligns with FDA recognitions like RaDaR's Breakthrough status and growing biopharma adoption for companion diagnostics, fueled by market forces such as NSCLC prevalence and immunotherapy advances.[1][2] By partnering with pharma/biotech and integrating with NeoGenomics' oncology network, Inivata influences the ecosystem by accelerating MRD tools and real-world evidence, lowering barriers to genomic testing and enabling earlier interventions.[1][5]

Quick Take & Future Outlook

Post-2021 acquisition, Inivata—now under NeoGenomics—prioritizes RaDaR® commercialization for clinical launch and biopharma expansion, leveraging combined resources for faster growth.[1] Trends like AI-enhanced ctDNA analytics and multi-cancer early detection will shape its path, potentially expanding beyond NSCLC/MRD into pan-cancer applications. Its influence may evolve by setting benchmarks for sensitivity in liquid biopsy, driving broader adoption in routine oncology and solidifying NeoGenomics' diagnostics leadership—unlocking genomic insights from blood to transform cancer outcomes, as pioneered from Cambridge labs.[1][2]